Professional Documents
Culture Documents
CJ Bio Pharma English
CJ Bio Pharma English
1
CJ CheilJedang Bio has become the world’s leading bio
company thanks to its competitiveness and investment in
R&D. CJ CheilJedang Bio commits to being a global green bio
company by bolstering its product competitiveness, especially
for ‘Nucleotide’ and ‘Lysine,’ which are leaders in the global
market, expanding global production facilities and securing
new engines for global growth.
17
CJ Healthcare leads the domestic ETC, API and Health&Beauty
markets. With the establishment of the Osong Plant which
complies with the cGMP standard to go global, CJ Healthcare
has laid the foundation to be a leading global pharmaceutical
company.
CJ CHEILJEDANG BIO CJ HEALTHCARE
2 3
51 2017 * 4,000
NO.1
42 2012 1,500
35
CJ CheilJedang Bio, 2011 1,200
24
a Global Leader in Advanced Bio Products 23 23 NO.1 2010 956
2009 706
2010 2011 2012
CJ CheilJedang Bio business is a global leader in the feed amino acid and fermented nucleotide market for food.
Starting with the production of MSG in 1964, CJ CheilJedang Bio produces ‘Lysine,’ ‘Threonine,’ ‘Tryptophan,’ CJ Tide(nucleotide) L-Lysine * 2017 Sales Forecast
‘Nucleotide’ and ‘MSG’ at seven overseas plants based on its micro-organism fermentation technology that has been
developed over the past 50 years. CJ CheilJedang Bio reached sales of 1 trillion won in 2010, meaning it played a
pivotal role in the health of CJ’s global business. CJ CheilJedang Bio has established the competitive edge it needs
to compete globally through expanding its business scale. It currently strives to enter the environmentally friendly bio
business by producing the world’s first ‘L-form Methionine,’ functional amino acids, non-edible biomass and bio-plastic.
BUSINESS AREA
Animal Nutrition | CJ CheilJedang Bio Business is a leading manufacturer in the global feed amino acid market.
Feed amino acids are essential nutrients for animal growth. CJ CheilJedang Bio Business currently ‘Lysine,’
HISTORY ‘Threonine,’ ‘Tryptophan’ and ‘Valine,’ with the largest global market shares for ‘Lysine’ and ‘L-Tryptophan.’ In
addition, it has developed the environmentally friendly technology required to produce ‘Methionine’ and is set to
CheilJedang Bio business started with the production of MSG in the 1960s and laid the foundation for success mass-produce it.
when it launched the world’s second nucleotide in the 1970s. CJ CheilJedang Bio entered the amino acid for
animal feed market around the 1980s and 1990s, which was the starting point for its entry in the global market. Food Ingredient | CJ CheilJedang Bio Business became the world’s second developer of ‘nucleotide’ in 1997
Having secured a number of production outposts around the world in the 2000s, CJ CheilJedang Bio is going after Japan and started expanding its ‘MSG’ and ‘nucleotide’ business. MSG and nucleotide are food enhancers
global at full throttle. to enhance the flavors and tastes of processed foods, which have seen a growth in the global market along with
the growth of the processed food industry. CJ CheilJedang Bio Business is a leader in the global nucleotide market
1964 Acquired Wonhyung Industry. Started producing and 2006 Completed Laocheng plant in China to and is expanding its product portfolio to health-related functional amino acids, including ‘Arginine,’ ‘Glutamine,’
selling ‘MIPOONG’(MSG) produce nucleotide and ‘BCAA.’ It commits to providing customers with health and joy through quality products.
1968 Started operating Gimpo Plant(to produce MSG) 2007 Completed Piracicaba plant in Brazil
1977 Became the world’s 2nd to successfully ferment and 2010 Launched ‘L-Tryptophan’ Future business | CJ CheilJedang Bio Business is preparing bio-based chemicals(raw materials for bio
produce ‘Nucleotide’ 2012 Completed Shenyang plant in China to produce plastic and bio-based chemicals) and the non-edible biomass business based on the innovative convergence
Developed IMP, GMP ‘Lysine,’ ‘Threonine’ of chemical process and catalyst technology with industrial strain development and fermentation technology.
Launched ‘AIMEE(MSG +0.5% of nucleotide)’ 2012 Started producing ‘MSG’ at Jombang plant
The environmentally-friendly bio-based chemicals are used as substitutes for chemical ingredients made from
1978 Established a plant for organic fertilizer 2013 Started producing the world’s first ‘L-Methionine’
petroleum-based resources and thus prevent natural resources from becoming depleted while also reducing
1988 Established PT. CHEIL SAMSUNG INDONESIA 2013 Launched edible amino acid, ‘L-Arginine’
greenhouse gas emissions. In addition, non-edible biomass is an effective substitute for materials from plant-based
(PT-CSI) in Indonesia 2013 Launched health-related functional amino acids
resources, and thus acts to contribute to making a sustainable and harmonious environment.
1991 Established Pasuruan plant(to produce ‘Lysine,’ MSG) 2013 Extended business areas to non-edible biomass and
1996 1st extension of Lysine line at Pasuruan plant bio-based chemicals(bio-plastic)
1997 Established Jombang plant(to produce nucleotide)
1999 Established BIO business unit
2000 Changed to BIO BU
2000 Launched ‘L-Threonine’
2005 Completed Laocheng plant in China to produce lysine
CJ CHEILJEDANG BIO CJ HEALTHCARE
4 5
Animal Nutrition
VISION
Beyond Bio,
Renew the
A Leader in the Global Feed Amino acid
Earth Market thanks to Unparalleled Technology
CJ CheilJedang is the number one global bio company in the green Environmentally Friendly policy,
ONLYONE Technology
bio market and a leader in the feed amino acid market. It leverages its
advanced fermentation and refining technology to produce feed amino The fermentation-based method to produce
MISSION
feed amino acids is environmentally friendly
acids including ‘L-Lysine,’ ‘L-Threonine,’ ‘L-Tryptophan,’ ‘L-Methionine,’
because it controls the glucometabolism
‘L-Valine’ and arginine. Feed amino acids are essential to animal growth of microorganisms, which enables it to use
(SOCIETY) (CUSTOMER) (EMPLOYEE) and supply the nutritional balance to animal growth when they are used in less energy and produce no pollutants. CJ
CheilJedang Bio Business has taken a further
Make the Earth Provide Work feed for pigs, chickens, horses and cows. The feed amino acid market is
step in support of the environment. It has
healthier with the best value with passion growing by a rapid 8-10 percent a year as the demand for meat increases made a large investment in the environment
green/white bio with advanced and joy the world over. at overseas plants to reduce wastewater and
products technology CJ CheilJedang Bio business has the largest market share in the global water usage, and eventually to establish a zero-
discharge system to preserve water resources.
‘L-Lysine’ and ‘L-Tryptophan’ markets through the establishment of a
Moreover, it has developed a high-yield strain
plant in Shenyang, China in 2012 and in Iowa, U.S.A. in the second half of to reduce raw and subsidiary materials and to
2013. Moreover, CJ CheilJedang Bio will become the first bio company decrease overall greenhouse gas emissions. It
Beyond the current working process, beyond the current technical boundary, works to protect the Earth and the ecosystem
to produce four major feed amino acids based on an environmentally-
beyond the current business areas, CJ CheilJedang Bio Business works to with its bio business ONLYONE technology.
friendly technical method, as it starts producing ‘L-Methionine’ from 2014.
pass on a sustainable and harmonious Earth to our children.
Moreover, CJ CheilJedang Bio will extend the product portfolio with the
launch of ‘L-Valine’ and ‘L-Arginine’ and the development of ‘Biotector,’
the world’s first environmentally friendly substitute to antibiotics. It commits
to leading the global market with highly valuable and environmentally
friendly bio products.
The CJ CheilJedang bio business has a vision of “Beyond BIO, Renew the Earth”, which
represents its commitment to do its best to maintain an ecosystem that’s sustainable for all
BIOMASS CO2
humans and animals. Its mission and duty is to pass on a sustainable Earth to our children
SUSTAINABILITY
by laying the foundation for growth and a sustainable ecosystem while protecting resources
and the environment. CJ CheilJedang Bio Business pledges to work hard to leverage its CJ BIO BIO PRODUCTS
6 7
Best Products
BESTAMINOTM
and cost competitiveness, take the top place in terms of market share. intake and reduces ammonia excretions. CJ CheilJedang Bio became the first manufacturer to commercialize successfully
Business continues to consolidate its leadership position in the ‘L-form Methionine’ with the environmentally-friendly bio
CJ has launched ‘L-Methionine,’ which accounts for 50 percent of the
global ‘lysine’ market with the advanced technology and cost engineering method based on raw sugar and glucose, which
feed amino acid market, and ‘L-Threonine,’ which enhances animal competitiveness. has the same structure as natural methionine and offers higher
growth based on environmentally friendly bio fermentation method. stability and usability.
CJ has recently developed ‘L-Valine’ after three years of research and
development. The environmentally-friendly ‘L-Valine,’ which helps to
promote animal growth, is enjoying rapid growth of more than 30 percent L-Tryptophan L-Threonine
a year. ‘Tryptophan’ is the third most rapidly depleted amino acid in ‘Threonine’ is the second or third most rapidly depleted
CJ CheilJedang Bio Business has established an exclusive portfolio of pigs. Tryptophan boosts the immune system by maintaining essential amino acid in animals. It promotes sound animal
feed mino acid products with its different level of technology and raw an internal protein balance that induces normal growth, and growth, and is involved in antibody creation that enhances
promotes antibody creation. As a precursor of serotonin the the performance of the cardiovascular, digestive, central
materials. ‘BestAmino’ will continue to grow as a leading brand in the
neurotransmitter tryptophan reduces animal aggressiveness, nervous, and immune systems. ‘L-Threonine’ is produced by a
global feed amino acid market.
as has been reported in research. CJ CheilJedang Bio’s fermentation process and contributes to promoting the growth
‘L-Tryptophan,’ which started being produced in 2010, currently of livestock, with cost reductions for livestock industry, and
holds the largest market share in the global market. enhanced environmental conservation.
L-Valine L-Arginine
‘Valine’ is the fifth most rapidly depleted amino acid in pig ‘Arginine’ carries nitrogen and is abundant in the body fluid of
feeds and a part of BCAA(Branched Chain Amino acid), along the fetus at the early and middle stages of pregnancy. ‘Arginine’
with leucine and isoleucine. The shortage of ‘Valine,’ which is aids protein synthesis, urea circulation and the excretion of
an essential nutrient for pigs and chickens, may cause nerve- nitrogen produced in the human body, and produces nitrogen
related problems. The use of ‘L-Valine’ or other BCAA with monoxide and polyamine that regulates the contraction and
feed helps the environment by reducing protein and ammonia release of blood vessels. It improves egg production and egg
excretions. weight, while maintaining the health of baby pigs and improving
the pregnancy outcome in pigs.
CJ CHEILJEDANG BIO CJ HEALTHCARE
8 9
Food Ingredient
‘Monosodium glutamate(MSG)’ and ‘nucleotide’ are major flavor The largest global market share,
CJ Tide (Nucleotide)
enhancers and food ingredients that have been improved with the
development of the fermentation technology of CJ CheilJedang Bio CJ CheilJedang Bio Business Unit has had the
largest market share in the global nucleotide
Business Unit. As they add a savory taste and enhance the natural flavor
market from 2011. With the establishment of a
and taste of food, they are often used to increase the taste and flavor of production facility in Indonesia and China, and
food products. the global sales network, CJ CheilJedang Bio We make more tastier and
Business supplies CJ Tides to the 70 countries healthier foods for the
‘MSG’ and ‘nucleotide’ naturally exist in foods but the amounts
around the world. The market share of CJ
ordinarily contained are too little to use commercially. Thus, ‘MSG’ and global market with safe and
CheilJedang’s nucleotide products will only
‘nucleotide’ are produced through a fermentation process which allows grow in the future. healthy ingredients.
a small amount of them to enhance taste and flavor greatly. ‘MSG’ and
‘nucleotide’ are currently used as core ingredients for all processed foods,
51%
including seasonings, Ramyun, pastes, sauces, snacks, and processed
meat and fish products.
Today, the global demand for ‘MSG’ and ‘nucleotide’ is over 3 million tons
and 4 million tons a year. The global demand for ‘nucleotide’ as a food No.1
enhancer continues to grow, especially in China, Southeast Asia, and 2013
Africa, due to its cost competitiveness and convenience. CJ CheilJedang
Bio Business has the largest market share in the world thanks to its
production competitiveness and its establishment of global supply
facilities. Its market share continues to grow each year. CJ CheilJedang
Bio Business expands the bio business to amino acids products based
on its amino acid fermentation technology. The recent well-being and
health trend is increasing the demand for health-related functional amino
acid products and CJ produces ‘L-Arginine,’ ‘L-Glutamine,’ and ‘BCAA’
to respond to this demand. CJ CheilJedang Bio Business will make
tastier and healthier foods for the global market with safe and healthy
ingredients.
CJ CHEILJEDANG BIO CJ HEALTHCARE
10 11
Best Products
‘Arginine’ is the only amino acid to produce nitrogen monoxide ‘BCAA(Branched Chain Amino acid)’ is a Branched Chain
Twenty amino acids are the essence of all living organisms. Amino acids that is a neurotransmitter regulating the contraction and release Amino acid, and includes ‘valine,’ ‘leucine,’ and ‘isoleucine,’
exist naturally and have a core function in living organisms. Amino acids of blood vessels. It enhances the cardiovascular system, which are among the nine essential amino acids for humans.
have become more widely used in recent years in the healthcare and muscles and vitality. It has been proved effective in the treatment ‘BCAA’ is an essential amino acid in muscle proteins and should
and recovery of sensitive teeth. With its strong moisture effect, be obtained through food intake as it is not naturally composed
personal care industry because they aid body functions and are not toxic
more skin and hair products use ‘Arginine’ and it offers the in the body. ‘BCAA’ enhances protein synthesis, muscle repair,
to the skin. The use of amino acids for industrial use has started to grow.
potential for use in healthcare foods and daily care products. the endurance and the recovery of muscle fatigue, and the use
CJ CheilJedang continues to innovate its amino acid products for added of ‘valine,’ ‘leucine,’ and ‘isoleucine,’ may increase. ‘BCAA’
value. L-Glutamine is becoming more widely used for sport nutrition along with
‘Glutamine’ as the sport industry grows. ‘BCAA’ is widely used
‘Glutamine’ is the most abundant free amino acid found in to treat patients suffering from cirrhosis and hepatic insufficiency
the body. It is a source of muscle energy and should be taken which hinders protein synthesis.
sufficiently to prevent muscle breakdown during intense exercise
or nutritional imbalance. ‘Glutamine’ has a synergy effect with
‘Arginine.’ As the sport nutrition market grows, ‘Glutamine’ is
facing rising demand. It is used as a source of nourishment in
food for patients as it increases muscle and organ repair.
CJ CHEILJEDANG BIO CJ HEALTHCARE
12 13
Global Activities
INDONESIA MALAYSIA CHINA U.S.A. BRAZIL
• First overseas production facility • Made a full entry into the • Production of lysine, threonine, • Global outpost for lysine production • Plays a connecting role
• Production of feed amino acid Methionine market and nucleotide • Entered the US market at full throttle • Easy to supply raw sugar
products and nucleotide • Penetrated the Chinese and
Asian market
1991 Established the Pasuruan plant 2014 Planned completion of the 2005 Established the Shandong plant 2014 Planned completion of the Green 2007 Complete the Lysine plant
1996 Established the Jombang plant Green Bio plant producing 2012 Established the Shenyang plant Bio plant producing 100,000
80,000 tons of Methionine a year tons of Lysine a year
RUSSIA
The core factor behind the global success of CJ CheilJedang Bio
Business has been its cost competitiveness. Its cost competitiveness is U.K. GERMANY KOREA
the result of three competitive edges: R&D, location, and global business FRANCE HUNGARY CHINA U.S.A.
PAKISTAN JAPAN
management. CJ CheilJedang Bio Business commits to bolstering its JORDAN
INDIA PHILIPPINES
market leadership in ‘Lysine,’ ‘Nucleotide’ and ‘Tryptophan,’ which are MEXICO
VIETNAM
currently leading the global market. NIGERIA THAILAND
MALAYSIA COLOMBIA
KENYA
CJ CheilJedang Bio Business has been extending its sales network by INDONESIA
PERU BRAZIL
reinforcing its global business network to provide customers with better SOUTH AFRICA
quality and service. CJ CheilJedang Bio Business will start producing AUSTRALIA
CHILE
‘Methionine,’ which accounts for over 50 percent of feed amino acids, ARGENTINA
from 2014 when the Malaysian plant is completed, and will assume
global leadership by producing the world’s first ‘L-form Methionine.’
In addition, it will diversify the product portfolio with functional amino
acids such as ‘L-Valine,’ ‘L-Arginine,’ and ‘Glutamine’ to secure a future GLOBAL SCENES
growth engine and enter the new business area of non-edible biomass
and bioplastic. It will establish a sustainable growth model by recycling
resources.
CJ CheilJedang Bio Business is leading the global bio industry, rather
than being content to be a leader in the amino acid business. It commits
CJ CheilJedang Bio Business is growing as a
to being the number one company in the global bio market by bolstering
global leader in the bio industry by establishing
its market dominance and securing a future growth engine. production facilities in Indonesia, the U.S.A.,
and Brazil.
CJ CHEILJEDANG BIO CJ HEALTHCARE
14 15
R&D Institute
Nucleotides
534
sustainable biomass using renewable resources, and on biomass to obtain
fermentable sugar from agricultural products, weeds, and wood waste.
AS OF 2013
16 17
Future Business
BIO-Based Chemicals
Non-Edible Biomass
18 19
2014 * 462.3
13.4%
2012 448.8
6.1%
CJ Healthcare, From a Domestic Leader to a Global Leader 2011 419.2
2010 361.2
CJ HealthCare was founded in 1984 and has established a firm lead in the Korean pharmaceutical market,
2009 289.3
particularly in ethical drugs(ETC) such as those treating cancer, problems with the circulatory system, diabetes, 80.5%
ETC 2008 339.8
and kidney disease, as well as API drugs, and in the health& beauty area. It acquired Hanil Pharmaceutical in 2004
H&B (Health&Beauty)
to reinforce its competitive edges in the pharmaceutical market. Over 200 professional researchers are engaged
Export * 2014 Sales Forecast
in R&D at CJ HealthCare to develop innovative therapeutic drugs for the circulatory system, metabolism,
gastrointestinal diseases, and cancer treatments. The company is committed to developing a pipeline for the
development of new drugs targeting gastrointestinal treatments, new anticancer drugs, bio drugs and renewed
therapeutic drugs through joint research with major hospitals, universities, and R&D venture companies.
BUSINESS AREA
HISTORY
ETC | CJ Healthcare produces ethical drugs(ETC) for cancer, circulatory diseases, diabetes, and gastrointestinal
1984 Started the pharmaceutical business. 2003 Registered ‘Pseudovaccin,’ a pseudomonas diseases. CJ Healthcare achieved a Korea first with its development of the renal anemia treatment ‘Epokine,’
Established a R&D center aeruginosa vaccine, and Korea’s 7th new drug. and has competitive ETCs including ‘Banan(antibiotics),’ ‘Herben(hypertension medicine),’ ‘Kremezine(Korea’s
1986 Completed Icheon Plant, launched the hepatitis 2004 Acquired Hanil Pharmaceutical first uremia drug),’ and ‘Anfrade(Chronic Arterial Occlusive Disease drugs).’ It provides patients with basic and
vaccine ‘Hepaccin-B’(only using locally developed 2006 Merged Hanil Pharmaceutical into CJ Pharma
nutritional fluid products and works to improve public health.
technologies) 2008 Entered into a joint investment agreement with
1990 Completed the Daeso plant ‘Neuralstem,’ a U.S. based stem cell research company to
API | CJ Healthcare is a leader in locally produced APIs which are the basis of high quality finished drugs. It
1990 Launched the cephalosporin antibiotics ‘7-ACA’ develop a therapeutic drug for the central nervous system
produces a range of APIs for oral drugs including cephalosporin antibiotics, leading the markets for finished drugs
1992 Completed the construction of a production facility 2008 Participated in a cord blood project run by
for intravenous solution the Seoul City government(investment in R&D by and APIs.
1992 Launched the hangover alleviation beverage ‘CONDITION’ Seoul National University)
1995 ‘Citopcin injection’ obtained the new technology mark 2010 Completed the construction of oral APIs H&B(Health&Beauty) | CJ Healthcare produces health/functional products along with ETC and API.
(KT Mark) and won the Changyeongsil Awards manufacturing buildings at Daeso Plant ‘CONDITION,’ which was launched in 1992 as a hangover alleviation drink, pioneered a new market and has
1995 Developed pseudomonas aeruginosa vaccine, 2010 Completed the construction of Osong Plant, remained number one in the market. ‘CONDITION’ has been improved through five renewals, and bolstered its
a world first built to meet global standards leadership in the market for hangover alleviation drinks with the release of ‘Hutgae CONDITION,’ which contained
1995 Reached over $100 million in export, a first for the 2011 Launched NBU(Nephrology Business Unit) and
Hutgae extract. ‘CONDITION Hut-gae-su’ launched the Hutgae tea market in Korea when it was released in 2010.
Korean pharmaceutical industry entered the kidney dialysis business
It became the number one Hutgae drink in the Korean market within just 16 months after launch, taking 50 per cent
1998 Launched the renal anemia treatment ‘Epokine’ 2012 ‘CONDITION Hut-gae-su’ became the No.1 drink product
of the market share thanks to its clear concept and positioning.
(first in Korea, third in the world) in terms of market share (As of 2012 Neilson Research)
1999 ‘Epokine’ won the Changyeongsil Awards 2012 Acquired a fluids manufacturing plant.
2000 Launched OBU(Oncology Business Unit) (Medi Pharma Plan Co.)
2000 Launched the new antiemetic ‘Campto,’ 2012 Selected as an ‘Innovative Pharmaceutical Company’
forging into the anticancer medicines market by the Ministry of Health
2001 Established the CJ CheilJedang Pharma 2014 CJ CheilJedang Pharma established
New Jersey office ‘CJ Healthcare’ Corporation
2002 Established the hepatitis B vaccine plant and began
exports to Myanmar
CJ HEALTHCARE
21
Heal
the World,
For the No. 1 Pharmaceutical Company
Better Life with Unmatched Global Competitiveness
philosophy of ‘Contributing to the National Economy.’ Its efforts to create the highest added finished products and cancer treatments, and pursues a CMO(Contract competence.
22 23
ETC API
CJ Healthcare successfully developed Korea’s first renal anemia drug Based on its knowhow and original fermentation technology, CJ
‘Epokine.’ It has since developed a number of IMDs and biomedicine Healthcare has started producing the active pharmaceutical ingredient
products in a range of areas, including for the circulatory system, of cephalosporin antibiotics ‘7-ACA’ and reached over 100 million
fluid, antibiotics, gastrointestinal diseases, kidney-related diseases, dollars in exports, the first Korean pharmaceutical company to do so.
endocrine system, CNS, cancer treatment, and urology. CJ Healthcare CJ’s Daeso plant produces the cephalosporin antibiotic ‘Banan’ and
is emerging as a top pharmaceutical company in the domestic market other high quality antibiotics, finished pharmaceutical products and
with its more than ten blockbusters, including ‘Banan(antibiotics),’ APIs. Widely recognized for its advanced technology by major global
‘Herben(hypertension medicine),’ ‘Kremezine(Korea’s first uremia drug),’ pharmaceutical companies, CJ exports API products to one of the major
and ‘Anfrade(Chronic Arterial Occlusive Disease drugs).’ Japanese pharmaceutical companies via CMO(Contract Manufacturing
Organization).
Gastrointestinal With therapeutic drugs for gastritis Kidney CJ Healthcare contributes to the life H&B(Health&Beauty)
medicine and reflux esophagitis, gastrointestinal quality and health of patients with chronic
simulants and others, CJ Healthcare works kidneyrelated disease thanks to its range
19.8 to the betterment of public health and 42.9 o f d ru g s t h a t t re a t re n a l a n e m i a and CJ Healthcare has a range of health/functional products such as
billion won globalization of the business by building a billion won chronic renal failure, growing as a total care
‘Hutgae CONDITION,’ ‘CONDITION Hut-gae-su,’ ‘CONDITION
strong drug development pipeline for the company through expanding its business
next generation of drugs. to dialysis.
Hwan,’ ‘Hongsamjin,’ and ‘Hongsamjin-Gold,’ all of which are best-
selling products. CJ Healthcare commits to providing consumers with
treatments for a healthier life.
Endocrine CJ Healthcare contributes to enhancing Circulatory CJ Healthcare has the highest quality of
medicine the recovery and life quality of diabetics circulatory medicines available, including
with effective high-quality products. With its for the treatment of high blood pressure,
37.4 continuous research and development into 69.3 abnormal hemostasis, and antithrombotic.
billion won new drugs, it is bolstering its leadership in billion won It is realizing the dream of good health and a
the domestic market. longer life.
Antibiotics CJ Healthcare has a range of antibiotics Anticancer CJ Healthcare has quality cancer treatment
including ‘Banan.’ It is leading the domestic and anti-emetic drugs that enable it to
antibiotic market with its diverse range of lead the domestic cancer treatment drugs
51.7 products. 55 market. It is extending its business to
Hutgae CONDITION, CONDITION Hwan Hongsamjin, Hongsamjin-Gold
billion won billion won adjuvant chemotherapy to promote the life
CONDITION Hut-gae-su
quality of cancer patients.
‘CONDITION’ was launched in 1992 ‘CONDITION Hwan’ launched in ‘Hongsamjin,’ ‘Hongsamjin-Gold’ is a
and created a new market overnight 2012, which added more convenience healthcare drink made from red ginseng.
Fluids CJ Healthcare brings safety and conve- Anti-inflammatory, C J H e a l t h c a r e i s a l e a d e r i n a n t i - for anti-hangover drinks in Korea. The to carrying around the existing It comes in a bottle and a pouch form. It’s
nience to the medical environment by respiratory, inflammatory, respiratory, neuropsy- sister product of ‘Hutgae CONDITION’ ‘CONDITION.’ It is made out of extracts a concentrate of 6 year old-red ginseng,
releasing core nutritional fluid products, neuropsychiatry c h i a t r y, a n d u r o l o g y. W i t h i t s a n t i - is ‘CONDITION Hut-gae-su,’ which was of willow trees, dried orange peel, deer antler extract, and Ganoderma
60.5 as well as various other products. CJ
and urology
inflammatory painkillers, asthma drugs, launched in 2010 and became the best and Maka, which help you to get rid lucidum. You can enjoy the flavor and
billion won Healthcare is a leader in the Korean fluid
market.
43.2 ADHD drugs and other diverse products,
it is growing as a leader in ETC.
drink made with Hutgae. of a hangover just by drinking it in the
morning after.
taste of real red ginseng.
billion won
CJ HEALTHCARE
24 25
RESEARCH AREA
R&D Center
New drug
Biologicals
development
Explore a leading Explore a candid which will shorten the time to develop candidate substances for new
Detect a disease Clinical trials Phase 1 Approval
substance to develop drugs and eventually lead to mutual growth with partners. CJ ONLYONE
CJ Healthcare R&D Center, playing a
R&D Center, which is under construction, consolidates four business leading role to grow as the 2025 global
A pharmaceutical industry is a technical and R&D-intensive industry. The process Phase 2 areas of food, bio, pharma and feed& livestock, to maximize the synergies pharmaceutical company through
from exploring a candidate substance to its development, clinical trials, approval aggressive R&D investment.
among its businesses. ‘CJ Healthcare R&D Center’ will lead its growth to
and production takes over 10 years and costs tens of billions of money on
become a 2025 global pharma company through aggressive R&D and
average. CJ Healthcare has a strong drugs development pipeline with synthetic Phase 3
new drugs, natural and bio drugs that enable it to move forward as a global
successful results.
pharmaceutical company by 2025.
CJ HEALTHCARE
26 27
Infrastructure
CJ Healthcare produces quality drugs at its Osong, Icheon, and Daeso Production Infrastructure
plants through a strict quality control system. Its Icheon plant produces
bio drugs, its Daeso plant produces active pharmaceutical ingredients,
fluids, and cephalosporin antibiotics, and its Osong plant, which was
completed in 2010, produces cancer treatment drugs and finished
products. In particular, the Osong plant has a production facility that
meets the ‘cGMP’(Good manufacturing practice) standard required by
Icheon Plant • gene recombination products,
FDA/EU, which enables the plant to manufacture and manage products
vaccine, injection etc.
in accordance with the import regulations of the U.S.A. and other
advanced countries. Thus, the Osong plant is able to undertake out
the CMO business with major pharmaceutical companies. The Osong
Plant is production base that’s fit to compete on the global market and
was designed to enable expansion. The cutting-edge production facility
for bio drugs includes the second generation of EPOs, which is under
development at this moment, and will be built at the Osong plant. Daeso Plant • fluids, APIs, cephalosporin
antibiotics
CJ Healthcare has a EQMS(Enterprise Quality Management System)
in place with highly experienced experts in order to control quality at
every level from the development of drugs through to the use of drugs
by patients. It has implemented the highest level of CSV(Computer
System Validation) across all areas of the system. Moreover, CJ
Healthcare has introduced RFID, MES and LIMS systems to improve
the manufacturing and QC process. This has helped it to achieve cost Osong Plant • Cancer treatment, finished
savings and strengthen its competitive edge to compete at a global level. products
CJ Healthcare produces high quality drugs that meet the safety and
effectiveness standard and GMP standard by implementing an advanced
CJ Healthcare’s successful entry into emerging markets including
China and Southeast Asia is helping it to emerge as a leader in the enterprise quality management system at all levels from the research and
global pharmaceutical market. development of a drug to the treatment.
28
CJ Healthcare was not content to keep its sights solely on the domestic
market, as other pharmaceutical companies did, but seized the initiative to
expand internationally with APIs and finished pharmaceutical products that
leverage its expertise in biotechnology. In 1986, CJ Healthcare became the
first Korean company to develop the hepatitis vaccine ‘Hepaccin-B’ using
locally developed technology. CJ Healthcare in 1995 reached over 100
million dollars in exports, the first local pharmaceutical company to do so, and
successfully exported bio drugs with its renal anemia medicine ‘Epokine.’ CJ
Healthcare makes every effort to become a global pharmaceutical company
by growing together with its business partners in R&D and sales, sharing
results, and conducting joint R&D. It entered into a joint investment project
in 2008 with the U.S.A.-based stem cell research company ‘Neuralstem,’
to develop a therapeutic stem cell drug for the central nervous system and
completed a license contract on ‘RQ-4,’ the candidate substance to control
gastric acid with the Japanese ‘RaQualia Pharma’ in 2010. It has bolstered
its pipeline for gastrointestinal drugs in order to complete a license contract
on 5-HT4 partial agonist ‘RQ-10’ in 2011. It creates value by entering into a
license contract on various candidate substances and new drugs with major
pharmaceutical companies.
CJ Educations
330, Dongho-ro, Jung-gu, Seoul
CJ CheilJedang Center
TEL. 02-2008-5800
FAX. 02-2275-8550
www.cjithink.com